CAR T-cell therapy is used to treat patients with blood cancers such as multiple myeloma. Since it can cause serious side effects, patients are usually hospitalized and monitored for up to two weeks after therapy. With treatments generally only offered at large cancer centers, they can be difficult to access for many patients. Join Dr. Sridevi Rajeeve, Myeloma and Cell Therapy Oncologist at Memorial Sloan Kettering Cancer Center, and Todd Greenwood, Senior Director of Evidence and Outcomes at ZS, as they discuss how wearable remote patient monitoring devices could change the way this therapy is offered.
You’ll learn more about:
- CAR T-cell therapy risks and the challenges presented by the traditional way the therapy is offered
- Results of clinical trials conducted using wearable remote patient monitoring devices
- How remote patient monitoring could make CAR T-cell therapy more accessible and cost-effective